Previous 10 | Next 10 |
home / stock / sva:cc / sva:cc news
Sernova (TSX: SVA) is a clinical-stage biotechnology company developing therapeutic cell technologies with a goal to deliver a 'functional cure' for chronic diseases, including insulin-dependent diabetes, thyroid disease and hemophilia A. Sernova has developed the Cell Pouch System(TM), an impla...
Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid gland Sernova has engaged with regulatory authorities towards initiating clinical development of a prospective therapy ...
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia iPSC islet-like cluster manufacturing scale-up and te...
LONDON, Ontario, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the...
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participation Transplantation of islets into the enhanced 10-channel Cell Pouch is anticipated in early 2023 Company continues to anticipat...
LONDON, Ontario, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be presenting at the upcoming Stifel Healthcare Conference being held in-person in New York, NY on Nove...
Sernova plans to begin enrollment of second cohort in the coming weeks and implant multiple patients with the enhanced capacity 10-channel Cell Pouch before the end of 2022 Positive interim results from patients in the first cohort informed the islet dose and density threshold optim...
(TheNewswire) London, Ontario – TheNewswire - October 24, 2022 - Sernova Corp. (“ Sernova ” or the “ Corporation ”) (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH) announces that it has changed its auditor to KPMG LL...
LONDON, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced it will be presenting at the upcoming Roth Inaugural Healthcare Opportunities Conference being he...
LONDON, Ontario, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE / XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced that all remaining share purchase warrants related to the 2020 private placement, expiring on S...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment o...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...